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Bioprostheses “Thrombosis” After
entTo the Editor: Surgical replacement of the aortic valve reduces
symptoms and improves survival in patients with symptomatic and
severe aortic stenosis (1). Transcatheter aortic valve replacement
(TAVR) provides a safe and efficient alternative for inoperable and
high-risk surgical patients (2–4).
Available guidelines recommend aspirin for all patients with
biological prosthetic heart valves and for those with no risk factors
for thromboembolism. After TAVR, it is common practice to
prescribe antiplatelet therapy only.
No cases of valve thrombosis were reported after TAVR in 1
randomized trial and in large-scale registries (4 –6). In the
PARTNER EU (Randomized Placement of Aortic Transcatheter
Valves Trial European) Study (7), only 1 case of valve thrombosis was
reported. This patient required explant on day 257.
We report here on 3 cases of bioprostheses dysfunction due to
leaflet thrombosis after TAVR.
Case 1 was an 80-year-old woman with severe aortic valve
stenosis who underwent TAVR (23-mm Sapien XT, Edwards
Lifesciences Inc., Irvine, California). The patient was discharged
home as asymptomatic on day 5 on dual antiplatelet therapy
(DAPT). At discharge, transthoracic echocardiography (TTE)
showed normal function of the aortic prosthesis, with a mean
pressure gradient (MPG) of 10 mm Hg. At 1-month follow-up, a
MPG of 12 mm Hg was observed. At 10 months, the patient was
symptomatic for dyspnea (New York Heart Association [NYHA]
functional class III), and TTE showed severe aortic restenosis with
a MPG of 54 mm Hg (Vmax 510 cm/s). Transesophageal echo-
ardiography (TEE) showed fusion of 2 leaflets with suspicion of
thrombotic apposition” (Figs. 1A and 1B). Screening tests for
hrombophilia, allergy to valve components, and systemic inflam-
ation activation were all negative.
Oral anticoagulation therapy (OAT) was prescribed. After 3unction (MPG 13 mm Hg), and the patient was asymptomatic.
wo months after discontinuing OAT, the patient is still
symptomatic, and the aortic bioprostheses is functioning
roperly.
Case 2 is a 81-year-old man with severe dysfunction of the
ortic valve bioprostheses (25-mm Carpentier Edwards, Ed-
ards Lifesciences) who underwent TAVR (23-mm Sapien XT,
dwards Lifesciences). The patient was discharged home as
symptomatic on day 5. At discharge, TTE showed normal
unction of the aortic prosthesis (MPG 15 mm Hg). At
-month follow-up, a MPG of 14 mm Hg was observed. At 4
onths, the patient was symptomatic for dyspnea (NHYA func-
ional class III), and TTE showed severe aortic restenosis with a
PG of 51 mm Hg (Vmax 4.24 cm/s). TEE showed fusion of 2
eaflets with a suspicion of thrombotic apposition. OAT was pre-
cribed. After 2 months, TEE showed restored bioprostheses function
MPG 9 mm Hg), and the patient was asymptomatic.
Case 3 involved a 74-year-old woman with severe aortic valve
tenosis who underwent TAVR (26-mm Sapien XT, Edwards
ifesciences). The patient was discharged home as asymptom-
tic on day 4 on DAPT. At discharge, TTE showed normal
unction of the aortic bioprostheses (MPG 7 mm Hg). At
-month follow-up, a MPG of 8 mm Hg was observed. At 2
onths, the patient was symptomatic for dyspnea (NHYA
unctional class II), and TTE showed severe aortic restenosis with
MPG of 34 mm Hg (Vmax 328 cm/s). TEE showed a suspicion
f thrombotic apposition blocking the movement of a bioprosthe-
es leaflet. OAT was prescribed. After 2 months, the patient was
symptomatic, and TEE showed restored bioprostheses function
MPG 9 mm Hg).
Edwards SAPIEN aortic valve stents (Edwards Lifesciences)
re manufactured in the same way as conventional aortic biopros-
heses, and they should have the similar thrombogenicity. For this
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therapy and no oral anticoagulation.
In all 3 reported cases, valve thrombosis was resolved with
OAT, and the patients did not require open-heart surgery.
We believe that this report can be hypothesis-generating to
design a trial aimed at identifying the proper antiplatelet or
anticoagulation therapy after TAVR and to identify therapy for
bioprostheses thrombosis.
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Figure 1 Echocardiography of Aortic Valve Bioprostheses 3 Mo
Transesophageal (short axis) identified thrombus (red arrows) on the bioprosthese
peak aortic flow velocity (Vmax 510 cm/s) (C). After 3 months of oral anticoagulati
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